Comparative Pharmacology
Head-to-head clinical analysis: CERADON versus MAGNACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CERADON versus MAGNACORT.
CERADON vs MAGNACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown; possibly enhances cognitive function by modulating cholinergic and dopaminergic pathways.
Corticosteroid receptor agonist; modulates gene transcription to produce anti-inflammatory and immunosuppressive effects.
500 mg orally every 8 hours; for severe infections, 750 mg every 12 hours or 1 g every 8 hours.
5 mg orally once daily for 7 days, then 5 mg orally every other day for 7 days. Alternatively, 1 mg/kg intravenously every 12 hours for 14 days.
None Documented
None Documented
3-5 hours in healthy adults; prolonged to 8-12 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 20 hours in severe impairment (CrCl <30 mL/min).
3.5 ± 0.8 hours (terminal); prolonged in renal impairment (up to 12 hours in ESRD) and hepatic disease; requires dose adjustment in CrCl <30 mL/min
Renal: 60-70% unchanged; biliary/fecal: 20-30% as metabolites; total: >90% eliminated within 48 hours.
Renal (80% as unchanged drug and metabolites, primarily via glomerular filtration and tubular secretion); biliary/fecal (15%)
Category C
Category C
Corticosteroid
Corticosteroid